Institute of Human brain RAS

Saint Petersburg 197376

0 studies enrolling now · 3 studies all time

What they study most

Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting

Studies at this site

• Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis — Completed
• A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis — Completed
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One — Completed